NEW! Investment Companies Centre

Oxford Bio jumps on TroVax trial change approval

Related Companies

Related Indices

Related Sectors

News for Spread Betters

PreviousPrevious
NextNext

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here. Advertisement

Date: Tuesday 07 Oct 2008

LONDON (ShareCast) - Shares in Oxford Biomedica surged ahead after positive talks with the US Food and Drug Administration (FDA) on further trials for its renal cancer drug TroVax.

The group slumped in July after a key safety monitoring board said final stage clinical trial of TroVax, which is being developed with French drugmaker Sanofi-Aventis, would not meet its defined goals.

Oxford said today that the FDA supported all aspects of its amended plan for the Phase III TRIST study of TroVax.

The FDA agreed to review additional data from the TRIST study, which Oxford BioMedica is currently collecting from clinical sites.

It has also offered to continue its dialogue with Oxford BioMedica and Sanofi-Aventis to determine the path forward for further trials.

“We are encouraged by the FDA’s feedback and guidance," said acting chief executive of Oxford Biomedica John Dawson.

"The agreed amendments to the TRIST study should enable us to identify the optimal setting and regimen for TroVax in renal cancer and we remain optimistic that TroVax may show benefit in a subset of patients," he added.

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).